Altimmune Inc ALT 深 滬
等待開盤 01-29 09:30:00 美东时间
5.7985
-0.381
-6.17%
華盛通- 最 高6.36
- 今 開5.97
- 成交量 562.67万股
- 最 低 5.60
- 昨 收 6.18
- 總市值 6.03亿
- 52周最高 7.73
- 市盈率 靜 --
- 換手率 5.41%
- 52周最低 2.90
- 委 比 20.00%
- 總股本 1.04亿
- 歷史最高 237.30
- 量 比 1.69
- 振 幅 12.30%
- 歷史最低 1.51
- 每 手 1
- 風險率 1.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers ENvue Medical (NASDAQ:FEED) stock moved upwards by 19.0% to $1.25 duri...
01-28 20:05
Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline
Altimmune ($ALT) has raised $75 million in new funding, giving the biotech comp...
01-28 16:09
Altimmune prices $75M direct offering
Altimmune (ALT) entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17.05M shares pursuant to a registered direct offering. The offe...
01-28 12:39
Booz Allen Posts Upbeat Q3 Earnings, Joins Life360, Redwire And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Dow Jones falling around 200 points on Friday....
01-23 23:55
生物科技股强势上涨，标普生物科技ETF涨2.32%
截止1月22日10点11分，上证指数涨0.54%，深证成指涨0.45%，创业板指涨0.58%。油气开采及服务、可燃冰、军工装备等板块涨幅居前。 ETF方面，标普...
01-22 10:59
Enovix, Serve Robotics, EOG, Altimmune, Globalstar Shake Markets
Insiders have been trading these 5 stocks: (($ENVX)), (($SERV)), (($EOG)), (($A...
01-10 21:01
Why Are Investors Looking At Altimmune Stock?
Shares of Altimmune, Inc. (NASDAQ: ALT) are rising Monday after the FDA granted Breakthrough Therapy Designation for Pemvidutide.
01-06 00:04
Market-Moving News for January 5th
ALT: 24% | Altimmune shares are trading higher after the FDA granted Breakthrough Therapy Designation for Pemvidutide in MASH. RDHL: 52% | RedHill Expands RHB-102 Clinical Development Addressing GLP-1
01-05 20:44
Altimmune Says FDA Grants Breakthrough Therapy Designation For Pemvidutide, Balanced 1:1 Glucagon/GLP-1 Dual Receptor Agonist, For Treatment Of Patients With MASH
Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough
01-05 20:33
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Altimmune's pemvidutide has received FDA Breakthrough Therapy Designation for treating metabolic dysfunction-associated steatohepatitis (MASH) based on phase 2b data showing significant liver improvements. Phase 3 trial parameters are aligned with FDA, with plans to evaluate multiple doses over 52 weeks.
01-05 12:30
